Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, announced the presentation of new data on its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference, held in London, United Kingdom. The presentation, titled "Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies," was delivered by Jonathan Davis, PhD, Director of ADC Discovery at Helix BioPharma, on the opening day of the conference.
CEACAM6 is a highly attractive therapeutic target due to its elevated expression across a broad range of epithelial cancers, its association with poor clinical outcomes, and its limited expression in healthy tissues. Dr. Davis presented data supporting the tumor-selective binding profile of Helix's proprietary anti-CEACAM6 VHH, a single-domain antibody fragment derived from camelid antibodies, also known as a nanobody. This fragment demonstrated preferential binding to tumor-expressed CEACAM6, supporting the development of next-generation ADCs designed to deliver potent therapeutic payloads directly to cancer cells while minimizing off-target effects. The program builds on the clinical foundation set by Tumor Defense Breaker™, L-DOS47, Helix's lead CEACAM6-targeted candidate, which has shown favorable safety and encouraging clinical activity in Phase I/II studies in non-small cell lung cancer (NSCLC).
"CEACAM6 represents a compelling and underexploited target with broad potential across multiple hard-to-treat cancers," said Dr. Davis. "Our proprietary VHH-based targeting approach enables highly selective tumor binding, supporting the development of next-generation ADCs designed to maximize therapeutic impact while minimizing off-target effects." The presentation generated strong interest among conference participants, reflecting growing recognition of CEACAM6 as an important emerging target in oncology. A copy of the presentation is available on the Company's website at https://helixbiopharma.com/wp-content/uploads/2026/02/Unlocking-the-Potential-of-CEACAM6.pdf.
The World ADC London conference is the longest-standing global conference dedicated to ADC research and development, now in its 16th year. It brings together over 700 industry stakeholders from more than 240 companies, including biopharma organizations, clinicians, investors, and regulatory experts, as well as a faculty of over 120 speakers. The conference provides a forum for scientific exchange and collaboration to advance next-generation ADC innovation. More information can be found at https://worldadc-europe.com/.
Helix BioPharma is an oncology company that innovates to bring near-term solutions for hard-to-treat cancers. The pipeline includes L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy, and next-generation bi-specific ADCs in discovery. The Company also advances two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug. Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). For more information, visit https://www.helixbiopharma.com/.
